Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL


Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Sattva Neelapu, MD, a professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma (MCL).

Brexucabtagene autoleucel (brexu-cel; Tecartus) was approved by the FDA in July 2020 for relapsed/refractory MCL, and shares many similarities with axicabtagene ciloleucel (axi-cel; Yescarta), which was approved by the FDA for use in adult patients with relapsed or refractory large B-cell lymphoma in October 2017, Neelapu says; the main difference between the products has to do with how they are manufactured.

In the multicenter phase 2 ZUMA-2 trial (NCT02601313), patients who received brexu-cel achieved a complete response (CR) rate of 67%, Neelapu notes. At a median follow-up of about 18 months, 48% of patients continued to respond to the product, according to data presented at the 2020 ASH Annual Meeting & Exposition.

Another product that is currently under review for patients with MCL if lisocabtagene maraleucel (liso-cel; Breyanzi), which is being examined in the phase 1 TRANSCEND NHL 001 trial (NCT02631044). An interim analysis presented at the 2020 ASH Meeting and Exposition examined outcomes with the agent in 32 patients. In total, 66% of patients achieved a CR, though a longer follow-up is needed in order to confirm the agent's benefit, Neelapu concludes.

Related Videos
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
Related Content
© 2023 MJH Life Sciences

All rights reserved.